← Leaderboards
Colin D Hall
University Of North Carolina Chapel Hill
$6,763,979
Attributed
$6,763,979
Total exposure
11
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $104.7K · FY2005–07$200K$150K$100K$50K$0
'05
'06
'07
Funding mix
By agency
NIH$6,763,979 · 11
By mechanism
M01$3,948,178 · 7
R01$2,815,801 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Charles Michael Van Der Horst$17,688,631
- Stephen M Pizer$6,533,419
- Thomas B Shea$581,749
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationAids TherapyHiv InfectionsDrug Screening /EvaluationAntiaids AgentAids /Hiv NeuropathyNeuropsychological TestsNeurotrophic FactorsRecombinant ProteinsAids Dementia ComplexGender DifferenceHuman Immunodeficiency Virus 1FemaleMicroorganism Disease ChemotherapyAntiviral AgentsMedical ComplicationPainDrug ToleranceAidsHuman Immunodeficiency VirusNervous SystemOpportunistic Infections
Grant awards (49)
NEUROLOGICAL RESPONSE TO HAART$35,455
M01 · FY2007 · RR · contact PI
NEUROLOGICAL RESPONSE TO HAART$94,621
M01 · FY2006 · RR · contact PI
CEREBROSPINAL FLUID HIV-1 AND COGNITIVE FUNCTION IN PATIENTS RECEIVING THERAPY$10,065
M01 · FY2006 · RR · contact PI
NEUROLOGICAL RESPONSE TO HAART$79,502
M01 · FY2005 · RR
CEREBROSPINAL FLUID HIV-1 AND COGNITIVE FUNCTION IN PATIENTS RECEIVING THERAPY$20,703
M01 · FY2005 · RR
SELEGILINE TRANSDERMAL SYSTEM IN HIV-ASSOCIATED COGNITIVE IMPAIRMENT$2,484
M01 · FY2005 · RR
Neurological Response to HAART$96,648
M01 · FY2004 · RR
Effects of HIV on the Nervous System in Women$10,298
M01 · FY2004 · RR
CEREBROSPINAL FLUID HIV-1 AND COGNITIVE FUNCTION IN PATIENTS RECEIVING THERAPY$6,338
M01 · FY2004 · RR
SELEGILINE TRANSDERMAL SYSTEM IN HIV-ASSOCIATED COGNITIVE IMPAIRMENT$3,962
M01 · FY2004 · RR
NEUROLOGICAL RESPONSE TO HAART$1
R01 · FY2004 · MH
NEUROLOGICAL RESPONSE TO HAART$363,750
R01 · FY2003 · MH
NEUROLOGICAL RESPONSE TO HAART$363,750
R01 · FY2002 · MH
EFFECTS OF HIV ON THE NERVOUS SYSTEM IN WOMEN$190,747
M01 · FY2002 · RR
RECOMBINANT HUMAN NERVE GROWTH FACTOR IN HIV ASSOCIATED NEUROPATHY$190,747
M01 · FY2002 · RR
PHASE III TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF 159U89 IN HIV-1$190,747
M01 · FY2002 · RR
RECOMBINANT HUMAN NERVE GROWTH FACTOR FOR THE TREATMENT OF HIV INFECTION$190,747
M01 · FY2002 · RR
NEUROLOGICAL RESPONSE TO HAART$363,750
R01 · FY2001 · MH
EFFECTS OF HIV ON THE NERVOUS SYSTEM IN WOMEN$294,555
M01 · FY2001 · RR
PHASE III TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF 159U89 IN HIV-1$294,555
M01 · FY2001 · RR
RECOMBINANT HUMAN NERVE GROWTH FACTOR IN HIV ASSOCIATED NEUROPATHY$294,555
M01 · FY2001 · RR
RECOMBINANT HUMAN NERVE GROWTH FACTOR FOR THE TREATMENT OF HIV INFECTION$294,555
M01 · FY2001 · RR
NEUROIMAGING IN HIV INFECTION$266,177
R01 · FY2001 · MH
RECOMBINANT HUMAN NERVE GROWTH FACTOR FOR THE TREATMENT OF HIV INFECTION$190,747
M01 · FY2001 · RR
EFFECTS OF HIV ON THE NERVOUS SYSTEM IN WOMEN$190,747
M01 · FY2001 · RR
PHASE III TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF 159U89 IN HIV-1$190,747
M01 · FY2001 · RR
RECOMBINANT HUMAN NERVE GROWTH FACTOR IN HIV ASSOCIATED NEUROPATHY$190,747
M01 · FY2001 · RR
CYTOSINE ARABINOSIDE FOR MULTIFOCAL LEUKOENCEPHALOPATHY IN HIV INFECTION$140,288
R01 · FY2001 · NS
HIV EFFECTS ON THE NERVOUS SYSTEM IN WOMEN$423,064
R01 · FY2000 · NS
NEUROLOGICAL RESPONSE TO HAART$362,500
R01 · FY2000 · MH
RECOMBINANT HUMAN NERVE GROWTH FACTOR FOR THE TREATMENT OF HIV INFECTION$294,555
M01 · FY2000 · RR
RECOMBINANT HUMAN NERVE GROWTH FACTOR FOR THE TREATMENT OF HIV INFECTION$294,555
M01 · FY2000 · RR
RECOMBINANT HUMAN NERVE GROWTH FACTOR FOR THE TREATMENT OF HIV INFECTION$294,555
M01 · FY2000 · RR
CYTOSINE ARABINOSIDE FOR MULTIFOCAL LEUKOENCEPHALOPATHY IN HIV INFECTION$273,591
R01 · FY2000 · NS
NEUROIMAGING IN HIV INFECTION$258,930
R01 · FY2000 · MH
RECOMBINANT HUMAN NERVE GROWTH FACTOR FOR THE TREATMENT OF HIV INFECTION$241
M01 · FY2000 · RR
EVALUATE THE SAFETY AND EFFICACY OF 159U89 IN HIV-1 PTS$0
M01 · FY2000 · RR
EFFECTS OF HIV ON THE NERVOUS SYSTEM IN WOMEN$0
M01 · FY2000 · RR
EFFECTS OF HIV ON THE NERVOUS SYSTEM IN WOMEN$0
M01 · FY2000 · RR
EFFECTS OF HIV ON THE NERVOUS SYSTEM IN WOMEN$0
M01 · FY2000 · RR
EFFECTS OF HIV ON THE NERVOUS SYSTEM IN WOMEN$0
M01 · FY2000 · RR
LAMICTAL IN ADULT SUBJECTS W/ HIV ASSOCIATED NEUROPATHY$0
M01 · FY2000 · RR
RECOMBINANT HUMAN NERVE GROWTH FACTOR IN HIV ASSOCIATED NEUROPATHY$0
M01 · FY2000 · RR
RECOMBINANT HUMAN NERVE GROWTH FACTOR IN HIV ASSOCIATED NEUROPATHY$0
M01 · FY2000 · RR
RECOMBINANT HUMAN NERVE GROWTH FACTOR IN HIV ASSOCIATED NEUROPATHY$0
M01 · FY2000 · RR
RECOMBINANT HUMAN NERVE GROWTH FACTOR IN HIV ASSOCIATED NEUROPATHY$0
M01 · FY2000 · RR
EVALUATE THE SAFETY AND EFFICACY OF 159U89 IN HIV-1 PTS$0
M01 · FY2000 · RR
EVALUATE THE SAFETY AND EFFICACY OF 159U89 IN HIV-1 PTS$0
M01 · FY2000 · RR
EVALUATE THE SAFETY AND EFFICACY OF 159U89 IN HIV-1 PTS$0
M01 · FY2000 · RR